00000000nam 2200000za 4500
0019.843746
003CaOODSP
00520221107152607
007cr |||||||||||
008170915s2017    oncd   #ob   f000 0 eng d
020 |a978-0-660-09724-4
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-192/2017E-PDF
24500|aUpdate on HIV-1 strain and transmitted drug resistance in Canada |h[electronic resource] : |bfindings from the Canadian HIV Strain and Drug Resistance Surveillance Program, 2012-2013.
24610|aFindings from the Canadian HIV Strain and Drug Resistance Surveillance Program, 2012-2013
260 |aOttawa : |bPublic Health Agency of Canada, |c2017.
300 |avi, 39 p. : |bgraphs
500 |a"Publication date: November 2017."
500 |a"Protecting and empowering Canadians to improve their health"--Cover.
500 |aIssued also in French under title: Mise à jour sur les souches du VIH-1 et la pharmacorésistance transmise au Canada : résultats du Programme canadien de surveillance des souches et de la résistance aux médicaments ayant trait au VIH, 2012-2013.
504 |aIncludes bibliographical references.
520 |a"HIV is a significant public health challenge. A key component in monitoring the epidemicis surveillance on HIV subtypes and drug resistance. Subtype B historically constituted over 95% of new diagnoses in Canada; however, the proportion of non-B subtypes has gradually been increasing and now represents about 20% of new diagnoses. Surveillance on HIV subtypes informs vaccine development and provides the opportunity to examine potential variation in transmission risk and treatment success by subtype. Moreover, national HIV drug resistance surveillance is important since transmission of drug-resistant HIV impacts treatment and also prevention and control activities. In 1998, the Public Health Agency of Canada (PHAC) created the Canadian HIV Strain and Drug Resistance Surveillance Program (SDR Program) to monitor HIV-1 subtypes and pre-treatment antiretroviral resistance in Canada. Six provinces collaborate with PHAC on this initiative: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Nova Scotia"--Executive summary, p. 3.
69207|2gccst|aAIDS (disease)
69207|2gccst|aDrug use
69207|2gccst|aImmunization
7102 |aPublic Health Agency of Canada.
77508|tMise à jour sur les souches du VIH-1 et la pharmacorésistance transmise au Canada |w(CaOODSP)9.843751
85640|qPDF|s1.21 MB|uhttps://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-192-2017-eng.pdf
986 |aPub.: 170240